Using MRI to predict chemotherapy response in children with retinoblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the use of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify prognostic factors that can predict how well children with retinoblastoma will respond to intra-arterial chemotherapy. Retinoblastoma is a common eye cancer in young children, and while treatment is generally effective, some patients experience early progression. By analyzing MRI results, the study aims to improve treatment outcomes by identifying which patients are likely to benefit from chemotherapy. The study focuses on children diagnosed with grade B to D retinoblastoma who are prescribed intra-arterial chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* grade B to D retinoblastoma
* prescription of intra arterial chemotherapy

Exclusion Criteria:

* none

Where it's running

• Fondation A De Rothschild
  Paris, France Recruiting

Study contacts

• Principal investigator: Augustin Lecler, MD — Fondation OPH A de Rothschild
• Study coordinator: Laurence Salomon, MD PhD
• Email: lsalomon@for.paris
• Phone: 0148036431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

  This study is testing whether high-dose Topotecan can help patients with recurrent retinoblastoma and vitreous seeds keep their eye while fighting the tumor.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai, China · NCT06972602

• Linking RB1 genetic changes to eye tumors and metastasis

  We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.

  Recruiting University of Washington · Seattle, Washington · NCT06725173

• Treatment for advanced retinoblastoma using a chemoplaque

  This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.

  Recruiting at 2 sites Phase 2 Targeted Therapy Technologies, LLC · New York, New York and 1 other locations · NCT06679634

• New treatment for children with hard-to-treat retinoblastoma

  This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai · NCT06424301

• Understanding the incidence and outcomes of trilateral retinoblastoma

  This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06367530

• Chemotherapy for high-risk retinoblastoma after eye removal

  This study is testing if giving chemotherapy after removing the eye can help prevent high-risk retinoblastoma from coming back in children with Stage I disease.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT05080010

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.